Eurotransplant experience with model for end-stage liver disease standard exceptions for hepatopulmonary syndrome and portopulmonary hypertension
European Respiratory Journal · 2026-11 · 68 (5) · 2600816
DOI: 10.1183/13993003.00816-2026 ↗Kurz gefasst
Leserbrief in der Zeitschrift European Respiratory Journal, online erschienen am 11.10.2026. Verfasst von Maïté Verstraeten und 12 weiteren Autor:innen. Beteiligte Einrichtung: Hepatology Research Unit, Department of Internal Medicine and Paediatrics, Ghent University, Ghent, Belgium. Die Arbeit nennt 14 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Fonds Wetenschappelijk Onderzoek, Stichting Tegen Kanker.
Abstract (Originalsprache)
Extract Hepatopulmonary syndrome (HPS) and portopulmonary hypertension (PoPH) represent distinct pulmonary vascular complications associated with portal hypertension and end-stage liver disease. While HPS results from intrapulmonary vasodilatations leading to hypoxemia, PoPH arises from pulmonary arterial remodelling, ultimately causing right heart failure [1, 2]. Both conditions substantially increase morbidity and mortality among liver transplantation candidates. Liver transplantation remains the only curative treatment for HPS, whereas its role in the management of PoPH remains uncertain and continues to be debated [3, 4].
Autor:innen und Institutionen
- Hepatology Research Unit, Department of Internal Medicine and Paediatrics, Ghent University, Ghent, Belgium.
- Department of Gastroenterology and Hepatology, Ghent University Hospital, Ghent, Belgium.
- Eurotransplant International Foundation, Leiden, The Netherlands.
- Division of Transplantation, Medical University of Vienna, Vienna, Austria.
- Department of Internal Medicine, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
- Sektion für Klinische Transplantationsmedizin, Klinik für Allgemeine, Viszeral-, Thorax-, Transplantations- und Kinderchirurgie, Universitätsklinikum Schleswig-Holstein (UKSH), Kiel, Germany.
Förderung
- Fonds Wetenschappelijk Onderzoek
- Stichting Tegen Kanker
Zitieren
APA
Verstraeten, M., Jens, A. J. T., Berlakovich, G., Sterneck, M., Braun, F., den Hoed, C. M., Trotovšek, B., Mikulic, D., Benkoe, T., Geerts, A., Verhelst, X., Van Vlierberghe, H., & Raevens, S. (2026). Eurotransplant experience with model for end-stage liver disease standard exceptions for hepatopulmonary syndrome and portopulmonary hypertension. European Respiratory Journal, 68(5), 2600816. https://doi.org/10.1183/13993003.00816-2026
Vancouver
Verstraeten M, Jens AJT, Berlakovich G, Sterneck M, Braun F, den Hoed CM, et al. Eurotransplant experience with model for end-stage liver disease standard exceptions for hepatopulmonary syndrome and portopulmonary hypertension. European Respiratory Journal. 2026;68(5):2600816. doi:10.1183/13993003.00816-2026
BibTeX
@article{Verstraeten2026,
author = {Verstraeten, Maïté and Jens, Axel J T and Berlakovich, Gabriela and Sterneck, Martina and Braun, Felix and den Hoed, Caroline M and Trotovšek, Blaž and Mikulic, Danko and Benkoe, Tamas and Geerts, Anja and Verhelst, Xavier and Van Vlierberghe, Hans and Raevens, Sarah},
title = {Eurotransplant experience with model for end-stage liver disease standard exceptions for hepatopulmonary syndrome and portopulmonary hypertension},
journal = {European Respiratory Journal},
year = {2026},
volume = {68},
number = {5},
pages = {2600816},
doi = {10.1183/13993003.00816-2026}
}
EUVIMED